# CheckMate 816 (NCT02998528)

> A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02998528
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Non Small Cell Lung Cancer
- Interventions: Nivolumab; Cisplatin; Vinorelbine; Gemcitabine; Docetaxel; Pemetrexed; Carboplatin; Paclitaxel; Ipilimumab
- Enrollment: 505
- Primary outcome: Event-Free Survival (EFS)
- Primary outcome: Pathologic Complete Response (pCR) Rate

## Commentary we found

- X threads: 184
- Podcasts: 164
- YouTube: 147
- X videos: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-816-nct02998528

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02998528", "email": "<work email>"}; the inbox owner confirms by the emailed link.